Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus.

Ferraro A, Buonocore SM, Auquier P, Nicolas I, Wallemacq H, Boutriau D, van der Most RG.

Hum Vaccin Immunother. 2019 May 31. doi: 10.1080/21645515.2019.1613126. [Epub ahead of print]

PMID:
31149870
2.

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.

Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, Tavares Da Silva F, Rappuoli R, Garçon N, Innis BL.

Vaccine. 2019 May 21;37(23):3006-3021. doi: 10.1016/j.vaccine.2019.04.048. Epub 2019 Apr 25. Review.

3.

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

Burny W, Marchant A, Hervé C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J; ECR-008 study group.

Vaccine. 2019 Mar 28;37(14):2004-2015. doi: 10.1016/j.vaccine.2019.02.015. Epub 2019 Mar 5.

4.

Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.

Ryser M, Berlaimont V, Karkada N, Mihalyi A, Rappuoli R, van der Most R.

Expert Rev Vaccines. 2019 Mar;18(3):309-322. doi: 10.1080/14760584.2019.1579647. Epub 2019 Mar 4.

PMID:
30739514
5.

Short-term and mid-term solutions for influenza vaccines.

Hanon E, Van der Most R, Del Giudice G, Rappuoli R.

Lancet Infect Dis. 2018 Aug;18(8):832-833. doi: 10.1016/S1473-3099(18)30404-3. No abstract available.

PMID:
30064669
6.

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.

van den Berg RA, De Mot L, Leroux-Roels G, Bechtold V, Clement F, Coccia M, Jongert E, Evans TG, Gillard P, van der Most RG.

Front Immunol. 2018 Mar 26;9:564. doi: 10.3389/fimmu.2018.00564. eCollection 2018.

7.

Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Van Deun K, Smilde AK, van den Berg RA, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, van der Most R, Didierlaurent AM.

NPJ Vaccines. 2018 Mar 21;3:13. doi: 10.1038/s41541-018-0047-7. eCollection 2018.

8.

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.

Moris P, Jongert E, van der Most RG.

Hum Vaccin Immunother. 2018 Jan 2;14(1):17-27. doi: 10.1080/21645515.2017.1381809. Epub 2017 Dec 1. Review.

9.

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.

Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, Janssens M, Leroux-Roels G, Marchant A, van den Berg RA, Garçon N, van der Most R, Didierlaurent AM; ECR-002 Study Group.

Front Immunol. 2017 Aug 14;8:943. doi: 10.3389/fimmu.2017.00943. eCollection 2017.

10.

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E, Didierlaurent AM, van der Most RG.

Front Immunol. 2017 May 23;8:557. doi: 10.3389/fimmu.2017.00557. eCollection 2017.

11.

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00553-16. doi: 10.1128/CVI.00553-16. Print 2017 Jun.

12.

[Improving pre- and perioperative hospital care : Major elective surgery].

Punt IM, van der Most R, Bongers BC, Didden A, Hulzebos EHJ, Dronkers JJ, van Meeteren NLU.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Apr;60(4):410-418. doi: 10.1007/s00103-017-2521-1. German.

PMID:
28258290
13.

Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.

Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, van den Berg RA, Ballou WR, Jongert E, Wille-Reece U, Ockenhouse C, Aderem A, Zak DE, Sadoff J, Hendriks J, Wrammert J, Ahmed R, Pulendran B.

Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2425-2430. doi: 10.1073/pnas.1621489114. Epub 2017 Feb 13.

14.

Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination.

Galson JD, Trück J, Kelly DF, van der Most R.

Sci Rep. 2016 Nov 16;6:37229. doi: 10.1038/srep37229.

15.

Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats.

Planty C, Mallett CP, Yim K, Blanco JC, Boukhvalova M, March T, van der Most R, Destexhe E.

Hum Vaccin Immunother. 2017 Jan 2;13(1):90-102. doi: 10.1080/21645515.2016.1227518. Epub 2016 Sep 14.

16.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M.

Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25.

17.

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

Canelle Q, Dewé W, Innis BL, van der Most R.

Hum Vaccin Immunother. 2016 Sep;12(9):2289-98. doi: 10.1080/21645515.2016.1168954. Epub 2016 Apr 22.

18.

Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences.

Galson JD, Trück J, Fowler A, Clutterbuck EA, Münz M, Cerundolo V, Reinhard C, van der Most R, Pollard AJ, Lunter G, Kelly DF.

EBioMedicine. 2015 Nov 24;2(12):2070-9. doi: 10.1016/j.ebiom.2015.11.034. eCollection 2015 Dec.

19.

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, Moris P, Hatherill M, Ofori-Anyinam O, Hanekom W; Vaccine Study Team, Bollaerts A, Demoitie MA, Kany Luabeya AK, De Ruymaeker E, Tameris M, Lapierre D, Scriba TJ.

Vaccine. 2015 Jul 31;33(32):4025-34. doi: 10.1016/j.vaccine.2015.05.088. Epub 2015 Jun 10.

20.

Retraction of the letter: "Comment on 'CD4⁺ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy' ".

van der Most R, Wettendorff M, Innis B, Hanon E.

Sci Transl Med. 2014 Sep 24;6(255):255rt2. doi: 10.1126/scitranslmed.3010397. No abstract available.

PMID:
25253677
21.

Seeking help: B cells adapting to flu variability.

van der Most RG, Roman FP, Innis B, Hanon E, Vaughn DW, Gillard P, Walravens K, Wettendorff M.

Sci Transl Med. 2014 Jul 23;6(246):246ps8. doi: 10.1126/scitranslmed.3008409.

PMID:
25101885
22.
23.

Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.

Roy-Ghanta S, Van der Most R, Li P, Vaughn DW.

J Infect Dis. 2014 Nov 1;210(9):1419-30. doi: 10.1093/infdis/jiu284. Epub 2014 May 26.

24.

Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.

van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E.

Hum Vaccin Immunother. 2014;10(3):572-6. Epub 2013 Dec 16.

25.

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD.

J Infect Dis. 2014 Mar;209(6):828-36. doi: 10.1093/infdis/jit651. Epub 2013 Nov 27.

26.

A previously unreported serious adverse event during balloon sinuplasty.

Hughes N, Bewick J, Van Der Most R, O'Connell M.

BMJ Case Rep. 2013 Jan 28;2013. pii: bcr2012007879. doi: 10.1136/bcr-2012-007879.

27.

Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity.

Brown MD, van der Most R, Vivian JB, Lake RA, Larma I, Robinson BW, Currie AJ.

Oncoimmunology. 2012 Oct 1;1(7):1084-1094.

28.

Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies.

McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA.

Cancer Immunol Immunother. 2013 Mar;62(3):529-39. doi: 10.1007/s00262-012-1360-z. Epub 2012 Oct 16.

PMID:
23069871
29.

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.

McCoy MJ, Lake RA, van der Most RG, Dick IM, Nowak AK.

Br J Cancer. 2012 Sep 25;107(7):1107-15. doi: 10.1038/bjc.2012.362. Epub 2012 Aug 21.

30.

Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP.

Gene Ther. 2012 Oct;19(10):999-1009. doi: 10.1038/gt.2011.169. Epub 2011 Nov 10.

PMID:
22071974
31.

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D; HPV-010 Study Group.

Hum Vaccin. 2011 Dec;7(12):1359-73. doi: 10.4161/hv.7.12.18282. Epub 2011 Dec 1.

32.

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M.

J Clin Immunol. 2011 Jun;31(3):443-54. doi: 10.1007/s10875-010-9490-6. Epub 2010 Dec 21.

33.

Age-dependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence.

Antonis AF, de Jong MC, van der Poel WH, van der Most RG, Stockhofe-Zurwieden N, Kimman T, Schrijver RS.

J Gen Virol. 2010 Oct;91(Pt 10):2497-506. doi: 10.1099/vir.0.020842-0. Epub 2010 Jun 16.

PMID:
20554798
34.

Innate immunity defines the capacity of antiviral T cells to limit persistent infection.

Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA.

J Exp Med. 2010 Jun 7;207(6):1333-43. doi: 10.1084/jem.20091193. Epub 2010 May 31.

35.

Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.

Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG.

J Immunol. 2009 Dec 15;183(12):7898-908. doi: 10.4049/jimmunol.0901060.

36.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
37.

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA.

PLoS One. 2009 Sep 10;4(9):e6982. doi: 10.1371/journal.pone.0006982.

38.

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.

Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ.

J Immunol. 2009 May 1;182(9):5217-24. doi: 10.4049/jimmunol.0803826.

39.

Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Blattman JN, Wherry EJ, Ha SJ, van der Most RG, Ahmed R.

J Virol. 2009 May;83(9):4386-94. doi: 10.1128/JVI.02524-08. Epub 2009 Feb 11.

40.

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.

van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA.

Cancer Immunol Immunother. 2009 Aug;58(8):1219-28. doi: 10.1007/s00262-008-0628-9. Epub 2008 Dec 4.

PMID:
19052741
41.

Immunogenic anti-cancer chemotherapy as an emerging concept.

Haynes NM, van der Most RG, Lake RA, Smyth MJ.

Curr Opin Immunol. 2008 Oct;20(5):545-57. doi: 10.1016/j.coi.2008.05.008. Epub 2008 Jun 23. Review.

PMID:
18573339
42.

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R.

Immunity. 2008 May;28(5):710-22. doi: 10.1016/j.immuni.2008.02.020. Epub 2008 May 8.

43.

Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors.

Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW.

J Immunol. 2008 Feb 1;180(3):1535-44.

44.

Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.

van der Most RG, Currie AJ, Robinson BW, Lake RA.

Cell Death Differ. 2008 Jan;15(1):13-20. Epub 2007 Nov 16. Review.

45.

Identification of a CD4 T cell epitope in the pneumonia virus of mice glycoprotein and characterization of its role in protective immunity.

Claassen EA, van Bleek GM, Rychnavska ZS, de Groot RJ, Hensen EJ, Tijhaar EJ, van Eden W, van der Most RG.

Virology. 2007 Nov 10;368(1):17-25. Epub 2007 Jul 16.

46.

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.

Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS.

Vaccine. 2007 Jun 15;25(25):4818-27. Epub 2007 Apr 20.

PMID:
17499893
47.

A better way for a cancer cell to die.

Lake RA, van der Most RG.

N Engl J Med. 2006 Jun 8;354(23):2503-4. No abstract available.

PMID:
16760453
48.

Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice.

Lukens MV, Claassen EA, de Graaff PM, van Dijk ME, Hoogerhout P, Toebes M, Schumacher TN, van der Most RG, Kimpen JL, van Bleek GM.

Virology. 2006 Aug 15;352(1):157-68. Epub 2006 May 30.

49.

Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides.

van der Most RG, Himbeck R, Aarons S, Carter SJ, Larma I, Robinson C, Currie A, Lake RA.

J Immunother. 2006 Mar-Apr;29(2):134-42.

PMID:
16531814
50.

Gene therapy for malignant mesothelioma: beyond the infant years.

van der Most RG, Robinson BW, Nelson DJ.

Cancer Gene Ther. 2006 Oct;13(10):897-904. Epub 2006 Jan 27. Review.

PMID:
16439992

Supplemental Content

Loading ...
Support Center